Depomed, Inc. has announced that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results